List view / Grid view

Issue #4 2015

 

Analysing recombinant proteins by mass spectrometry

5 December 2015 | By , , ,

The drug discovery landscape is changing: no longer limited to big pharma, it is now within reach of academics and small consortia alike. Regardless of the setting, drug discovery requirements are always the same: strong biological theory, good chemical starting material and high quality protein samples from which to determine…

Mass spectrometry and systems biology approaches in drug target discovery

5 December 2015 | By

Cells, organs and organisms are complex biological systems consisting of inter-related components that co-operatively work to maintain function and respond to change. Malfunction of any component can lead to pathologies and disease, leading to system-wide changes and subsequent adaptation. Hence, the ability to study and predict system behaviour will considerably…

Drug Target Review – Issue #4 2015

3 December 2015 | By Drug Target Review

Included in this issue: Biomarkers, Mass Spectrometry, Target Validation, Drug Development, Personalised Medicines, Next-Generation Sequencing, Protein Expression, Companion Diagnostics, and much more...

Mass Spectrometry In-Depth Focus 2015

3 December 2015 | By , , , ,

In this Mass Spectrometry In-Depth Focus: Michelle M. Hill from University of Queensland discusses Mass spectrometric and systems biology approaches in drug target discovery, and Nicola Burgess-Brown, Rod Chalk, Claire Strain-Damerell and Pravin Mahajan from the Structural Genomics Consortium look at analysing recombinant proteins by mass spectrometry...

Biomarkers as molecular footprints for cancer therapy: current perspectives and promises

3 December 2015 | By , , ,

Knowledge about cancer biomarkers has increased tremendously and provides clinicians and researchers with valued opportunities to understand the molecular mechanism of cancer, thus applying it to effective, early-stage diagnosis and treatment. Cancer biomarkers include a vast range of biochemical molecules such as nucleic acids, proteins, sugars, lipids, small metabolites, cytogenetic…

The challenges associated with ‘de-risking’ earlystage therapeutic targets

3 December 2015 | By , , ,

The pharmaceutical industry is searching for novel drug targets that could produce the next generation of ‘first-in-class’ therapeutic agents. The challenge for academia is to identify and translate such targets and to provide starting points and confidence in the underlying science. The aim should be to generate evidence that modulation…

3D printing: A new era for personalised medicines?

3 December 2015 | By

3D printing (3DP) is attracting increasing interest as a new method of fabricating pharmaceutical products, especially with the recent United States Food and Drug Administration (FDA) approval of the first three-dimensional (3D) printed tablet Spritam® (levetiracetam). 3DP is considered to be an additive manufacturing technique, because regardless of their principles of…

Next-generation transcriptomic analysis in cancer vascular research

3 December 2015 | By ,

Over the past decade significant advances have been made in the fields of genomic and transcriptomic profiling, inspired by the advent of next-generation sequencing (NGS). Yet despite the considerable promise of these new technologies, uptake has been slow. The focus of this review is the use of next-generation transcriptomic analysis…

Companion Diagnostics: Challenges in the development of pharmacist-based point-of-care tests

3 December 2015 | By ,

A 2010 overview article on companion diagnostics, compiled by authors Stephen Naylor and Toby Cole, commented on the need for the companion diagnostic to fit into the logistics of the testing laboratory. The intervening five years have shown that patients are demanding more rapid and more convenient testing for diagnosis,…

Send this to a friend